Medical device innovation: Guardant360 CDx
Guardant HealthGuardant360 CDx is an FDA-approved comprehensive liquid biopsy for all advanced solid tumors.
Guardant Health’s blood biopsy test provides complete genomic results in seven days for solid cancer tumors from genes recommended by the National Comprehensive Cancer Network. According to the company, Guardant360 detected 20% more patients with biomarkers than gold-standard tissue testing.
The test is also approved as a companion diagnostic to identify patients with non-small cell lung cancer who may benefit from treatment with pharmaceuticals.